Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Cempra's Solithromycin On Track To Enter Generic, But Resistant, CABP Market

Executive Summary

FDA schedules November advisory committee for Cempra's first-in-class antibiotic for community-acquired bacterial pneumonia.

Advertisement

Related Content

Recent And Upcoming FDA Advisory Committees
Recent And Upcoming FDA Advisory Committees
Recent And Upcoming FDA Advisory Committees
Recent And Upcoming FDA Advisory Committees
Recent And Upcoming FDA Advisory Committee Meetings
Recent And Upcoming FDA Advisory Committee Meetings
Recent And Upcoming FDA Advisory Committee Meetings
Cempra Details Launch Plans For Solithromycin
Antibiotic Discovery Hurdles: Could Data Sharing, Research Hub Solve Problem?
Time To Buy Cempra?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register